Showing posts with label Government Programs Summit 2014. Show all posts
Showing posts with label Government Programs Summit 2014. Show all posts

Friday, March 28, 2014

#GPSummit14: More from day 2

Our live coverage from IIR's 6th Annual Government Programs Summit has been provided by Katie Lapins, Director, Huron Consulting Group and Lori Greene, Manager, Huron Consulting Group . 


The theme around the afternoon sessions at this year’s GPSummit was documentation, documentation, documentation!!  The operational complexities when the Final Rule is published can be minimized tremendously if you have good documentation around your assumptions and processes.  One panel, led by Michael Panicaro from Revitas, focused on how manufacturers should be addressing their internal business objectives while developing an approach to identify the potential impacts of the Final Rule.  This session provided thoughtful insight as to how manufacturers should be preparing for the Final Rule and regardless of an organization’s size, how many products are currently marketed, or what is in the pipeline, every manufacturer will be affected.

Based on input from the conference attendees, most manufacturers have begun looking at what the Proposed Rule means to their organization, but few had gone as far as pulling data for modeling “what if” scenarios or advising other departments that could be impacted by the changes.  Most attendees expressed the opinion that CMS would issue the Final Rule by the end of May 2014, but a few others felt that it might be later in 2014.    As always there are going to be differences between what is in the Proposed Rule versus the Final Rule and interpretations and assumptions, especially before any additional guidance is issued, should always be documented.  Another point raised was that it is important that any assumptions or interpretations be consistent.  And of course, manufacturers should contact vendors to ensure that any system that provides data for the GP calculations, or performs the GP calculations, will be able to comply with the necessary changes and within the requisite time period. 

Food for thought…. One company in attendance has broken out the Proposed Rule into buckets.  For instance, with the possible expanded definition of “States” to include US Territories, which were previously excluded from the calculation of AMP and Best Price, the company located all of the data, entered it into their GP system, and analyzed the impact of the change to their numbers.  The biggest challenge for this company was locating where all of the data resided.

Tomorrow is another packed day focused on the 340B Program.  Of special note is the session with Commander Krista Pedley who oversees the Program.




Wednesday, March 12, 2014

The Advanced GP Forum, IIR GP Summit Pre-Conference Day, March 26th in Alexandria! Let’s talk GP!

Today's guest post has been provided by Chris Cobourn, Senior Vice President, Commercial Compliance.

 If I were to ask a Government Programs (GP) Professional “what’s on your mind?” I am pretty sure I would get an earful!

We are all pretty busy, facing significant challenges now while also trying to be prepared for the changes that will come with the CMS AMP Final Rule and HRSA’s Mega Rule. We have a lot to talk about, and the Advanced GP Forum is a great place to do it.

Over the last six years the Advanced GP Forum has become a must-attend event for anyone seeking in-depth, comprehensive examination of current and complex GP issues. The Advanced Forum breaks away from traditional presentations and provides insights from your peers in an open forum. As you know, there is a lot of gray area when it comes to guidance, yet the bar for compliance is set pretty high. That is why so many of you come to GP Summit and attend sessions like the Advanced GP Forum. It helps to promote dialog with your peers and understand the issues and how industry is dealing with them.

Myself and Erika Scholl from CIS facilitate the discussion, posing topics and questions to the panel, as well as seeking input from the audience. Some of the topics we will be discussing include:

• Shifts in the Payer mix with MMCO and HCX, and the expansion of Medicaid
• Medicaid and Medicare: An Overview of Healthcare Reform Impacts on Accruals and Liability
• Key components of the Final Rule and performing company specific Fiscal Impact analyses
• Key methodology topics across the programs
• Bona Fide Service Fee evaluations
• 340B Program Integrity initiatives, including manufacturer audits
• GP systems assessment and audit to validate the integrity of the calculations, both historical and prospective under the Final Rule

Panelists for this year’s Forum include: 

Tom Evegan, Senior Director, Commercial Contracting, CIS
Sharon Greeson, R.Ph., Strategic Consultant, Government Pricing and Programs and CIS State Medicaid Initiative leader
Jennifer Norton, Senior Director, Pricing & Contract Administration - Managed Markets, Vertex Pharmaceuticals, Inc.
Sabrina Yohai, Senior Corporate Counsel, Pfizer Inc.
Michael Hepburn, Sr. Director, Government Contract Compliance, Janssen Pharmaceuticals, Inc.
Paula Martins, Director, Contract Operations, Daiichi Sankyo

We in the industry take pride in the label “GP Geek.” We enjoy what we do, and we appreciate the opportunity to be with our fellow GP Geeks to discuss our shared challenges (as you know, there are not too many people who understand what we do!) We hope to see you there!

To hear more from Chris and CIS, join us for IIR's 6th Annual Government Programs Summit taking place March 26-28, 2014 in Alexandria, VA. Register with code GPBLOG25 and save 25%, offer ends 3/13 at midnight! To learn more, download our brochure. We hope to see you in a few weeks!




Wednesday, March 5, 2014

Ensure the Integrity of the 340B Program

http://bit.ly/1fFtkzMIIR’s 6th Annual Government Programs Summit is just 3 weeks away! Join Cmdr. Krista Pedley, PharmD, MS, CDR, USPHS, Director, Office of Pharmacy Affairs, HRSA, Chris Hatwig, President of Apexus, and other industry experts on the latest developments to the 340B Program.

Sessions throughout the conference will emphasize the role of the manufacturer in ensuring the integrity of the 340B program and will focus on:

• Updates regarding HRSA audits and other integrity initiatives
• Pricing and contracting strategies with the prime vendor
• Medicaid and duplicate discounts
• Orphan Drug Exclusion
• GPO Prohibition
• Contract Pharmacies

On Friday, March 28th, join Chris, along with other 340B experts in the sessions:

• Update on the 340B Program
• Latest Developments for the 340B Orphan Drug Rule

Plus! He will also be available in a parking lot Q&A session on Friday at the end of the track — 340B Summit for Manufacturers, in collaboration with Apexus' 340B University.

To learn more, download our agenda.

Register with code XP1951BLOG and receive 15% off of the standard rate: http://bit.ly/1dncAkp. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage.

We hope to see this March!

Cheers,
The GP Team

Opt-in for GP updates
GP Twitter
GP LinkedIn




Thursday, February 27, 2014

Hear from Eli Lilly, J&J, and Celgene on FFS, GP, AMP and more

http://bit.ly/1fsbl5OAt IIR’s 6th Annual Government Programs Summit, we provide you with varying perspectives on the way ACA ramifications have profound impact on the way you do business through engaging and interactive panel discussions. The following sessions—led by industry thought leaders and regulators will prepare you for the massive set of changes to the way the MDRP program is managed:

Developments in the Split between Managed Medicaid and Fee-For-Service
Josh O’Harra, Asst. General Counsel, Eli Lilly and Company
Andy Vasquez, Deputy Director, Texas Health & Human Services Commission (Invited)
Steve Liles, Pharm.D., Senior Director, Pharmacy Services, Goold Health Systems
Patricia Tietbohl, Director, Government Rebate Operations, Johnson & Johnson

What the GP Professional, Senior Management and the Board, Need to Be Aware of in a Merger or Acquisition
Chris Cobourn, Senior Vice President, Commercial Compliance, Compliance Implementation Services
Additional Panelists to be announced

Identifying How the AMP Final Rule Impacts Business Objectives and Developing an Adjustment Approach
Frank Prybeck, Director, Federal Government Pricing & Contract Administration, Celgene
Heather Dixson, Director, Government Price Reporting, Lilly USA, LLC 
Eric Lewis, Manager, Government Programs & Compliance, Baxter Healthcare Corporation 
Ken Nelson, Director, Johnson & Johnson 

Continually Strengthening Collaboration between States and Manufacturers
John Grotton, R.Ph., Executive Vice President, Goold Health Systems
Lisa Marchisello-Norton, Associated Consultant, Managed Healthcare Services, Lilly USA, LLC 
David Buckley, Contract Operations Mgr, Contract Management and Operations US, GlaxoSmithKline Cemeria M. Ehis, Pharmacy Rebate Analyst, Alabama XIX, HP Enterprise Services

To learn more, download our agenda.

Register with code XP1951BLOG and receive 15% off of the standard rate. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage.

We hope to see this March!

Cheers,
The Government Programs Team

Opt-in for GP updates
GP Twitter
GP LinkedIn




Monday, February 24, 2014

HRSA’s 340B Program Update, Managing the Coverage Gap, and a Full-Day of Final Rule Insight at IIR’s 6th Annual Government Programs Summit

http://bit.ly/OjZ6x0At IIR’s 6th Annual Government Programs happening March 26-28, 2014 in Alexandria, prepare for the impact of the U.S. Department of Health and Human Services June publishing of the 340B proposed rule and get practical solutions to manage the Coverage Gap Discount Program (CGDP) challenges.

Understand the rebates and forecasting involvement with the new Part D requirements in the session, Practical Solutions Manufacturers can use to Manage Coverage Gap Discount Program Challenges and hear from Cmdr. Krista M. Pedley, PharmD, MS, CDR, USPHS, Director, Office of Pharmacy Affairs, Health Resources and Services Administration, update the 340B program. Want more? Learn about the latest hot topic areas: Contract Pharmacies, Orphan Drugs, GPO Prohibition, Covered Outpatient Drugs, and Audits in the track — 340B Summit for Manufacturers, in collaboration with Apexus' 340B University.

New Podcast: Preview the Advanced GP Forum and Get Industry Insights from Chris Cobourn, SVP at CIS as he provides industry insights to:

• How manufacturers can navigate the challenge of forecasting Medicaid and Medicaid Managed Care
• Lessons learned on Bona Fide Service Fees and Fair Market Value
• The role of the GP professional evolving in a merger acquisition

Plus! Get a sneak preview from Chris on the one-of-a-kind Advanced GP Forum — Fiscal and Methodological Considerations of the Final Rule pre-conference day workshop, where you will receive a unique opportunity to obtain insights on critical GP issues from a panel of industry thought leaders. This full-day panel discussion will prepare for the individual components of the Final Rule and also discuss obtaining intelligence for planning and forecasting.

Listen to the full podcast.

To learn more, download our agenda. Register with code XP1951BLOG and receive 15% off of the standard rate. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage. We hope to see this March!

Cheers,
The Government Programs Team

Opt-in for GP updates
GP Twitter
GP LinkedIn




Thursday, February 20, 2014

Download the GP podcast featuring Chris Cobourn

http://bit.ly/MEIejrToday's podcast features Chris Cobourn, Senior Vice President of Commercial Compliance for CIS. Cobourn discussed his thoughts on the industry, as well as the challenge of forecasting Medicaid and Medicaid Managed Care, Bona Fide Services Fees and Fair Market Values, and mergers and acquisitions.

View our highlights below:

So before we begin, what are your thoughts on what’s going on in the industry today, Chris?

Chris: We are very much all in a “hurry up and wait” mode, especially from the pharmaceutical manufacturer perspective with continued delays of the final rule. But yet it is still really important to be as proactive as possible in your planning because when it hits, it could be significant and you really have to be in a comfortable position feeling that you‟ve planned for it.

Why is it important to conduct a company-specific impact analysis of the final rule?

Chris: At a high level, I think if you were to take a look at the question that we get increasingly from the CEO and CFO level, especially in smaller-sized companies where they are more involved, the simple question is: “What will the final rule mean to us and what will it take to implement it?”

When you look at all the variables and the proposed rule, if they all happen – and some of the significant things happen like the build-up rule, expansion of Medicaid to Puerto Rico, some of those types of things – it‟s significant. It‟s significant system changes, it‟s significant data that you‟ll need, it‟s significant materiality impact. So, how do you plan when you don't know which of those components will be in the final rule?

To hear more, download the full podcast.

Want to join Chris and CIS this March at IIR's 6th Annual Government Programs Summit? Register with code XP1951BLOG and receive 15% off of the standard rate. To view our full program, download our brochure. We hope to see you March 26-28 in Philadelphia, PA!







Friday, February 14, 2014

Part D Coverage Gap Discount Program Challenges


http://bit.ly/1gc8oVmThis year, new price and coverage dynamics kick-in for the Coverage Gap Discount Program (CGDP), which means all beneficiaries who enter the coverage gap will pay less for generic and brand-name drugs, with providers, manufacturers and CMS making up for the change. As most plans offer no Part D Prescription Drug gap coverage, this leaves some manufacturers little or no time to validate submitted invoices, its corresponding detail data, and prepare for the subsequent forecasting and rebates.

At the upcoming IIR's 6th Annual GP Summit in March, hear from Shannon Bermudez, Principal Consultant, Revenue Management, Life Sciences at Paragon Solutions in the session, Practical Solutions Manufacturers can use to Manage Coverage Gap Discount Program Challenges. Understand the challenges the Coverage Gap Discount Program has presented to pharmaceutical manufacturers and get practical solutions to manage these challenges to efficiently process payments under the CGDP within these deadlines.

To learn more, download our agenda.

Register with code XP1951BLOG and receive 15% off of the standard rate. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage. We hope to see this March!

Cheers,
The Government Programs Team

Opt-in for GP updates
GP Twitter
GP LinkedIn





Friday, February 7, 2014

HRSA Cmdr. Krista Pedley Provides 340B Update Preceding June Regulation

http://bit.ly/1bDNpJxThis March, IIR’s 6th Annual Government Programs Summit will once again welcome Cmdr. Krista M. Pedley, PharmD, MS, CDR, USPHS, Director, Office of Pharmacy Affairs, Health Resources and Services Administration, who will provide an update on the 340B program. The timing could not be better as a Memorandum Report released by the OIG this week spotlights inconsistencies within the 340B program.**

With the U.S. Department of Health and Human Services publishing the 340B proposed rule in June triggering an increase in transparency to the 340B program, you'll best prepare for the impact of these changes in the track - 340B Summit for Manufacturers, in collaboration with Apexus' 340B University. Hear updates and learn about the latest details in these key hot topic areas: Contract Pharmacies, Orphan Drugs, GPO Prohibition, Covered Outpatient Drugs, Audits, and more!

To learn more, download our agenda.

Register with code XP1951BLOG and receive 15% off of the standard rate. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage. We hope to see this March!

Cheers,
The Government Programs Team

Opt-in for GP updates
GP Twitter
GP LinkedIn




Thursday, January 23, 2014

Prepare for 340B Program Changes and the AMP Final Rule

http://bit.ly/1l1eug1As the clock ticks down on the few months left before the AMP Final Rule is released, IIR's 6th Annual Government Programs Summit in March will be your last opportunity to hear from colleagues who have prepared for the impact of each individual component of the rule:

This full day panel discussion will prepare for the individual components of the Final Rule and also address the combined GP and Finance concerns that manufacturers are facing for planning and forecasting. Because Q2 publication of the long-awaited CMS AMP Final Rule will have a financial impact and affect forecasting, gross-to-net, and accruals, it is no longer exclusively a GP issue and is just as important for a company's Finance organization to prepare for the changes.

Panelists:
Jennifer Norton, Senior Director, Pricing & Contract Administration - Managed Markets, Vertex Pharmaceuticals
Sabrina Yohai, Senior Corporate Counsel, Pfizer
Michael Hepburn, Sr. Director, Government Contract Compliance, Janssen Pharmaceuticals

CIS Speakers:
Chris Cobourn, Senior Vice President, Commercial Compliance
Erika Scholl, Senior Manager, Government Programs Consulting
Tom Evegan, Commercial Contracting Services

340B Summit for Manufacturers - In collaboration with Apexus' 340 University

The 340B universe is changing and this means various things for manufacturers. There is increased scrutiny as to the level of 340B compliance for all stakeholders, including manufacturers' compliance with pricing as well as covered entities' compliance with program requirements. OPA has begun publishing audit results from 340B covered entities, promising crucial information on covered entities' compliance with the program. Get access to the experts in an interactive session tailored for manufacturers. Learn the latest in these key hot topic areas: Orphan Drugs, GPO Prohibition, Covered Outpatient Drugs, Audits, and more!

Speakers:
Cmdr. Krista M. Pedley, PharmD, MS, CDR, USPHS, Director, Office of Pharmacy Affairs, Health Resources and Services Administration
Christopher Hatwig, MS, RPh, FASHP, President, Apexus, 340B Prime Vendor Program
Larry Stepp, Vice President, National Accounts, AmerisourceBergen
Perry Knight, Senior Counsel, Johnson & Johnson
Robert Nahoopii, PharmD, MS, BCPS, CEO/Co-Founder, Turnkey Pharmacy Solutions, A 340B Management Company


To learn more, download our agenda.

Register with code XP1951BLOG by this Friday (1/24) and receive up to $400 off of the standard rate. If you have any questions about the event, feel free to contact Kate Devery (Kdevery@iirusa.com) For more information visit our homepage. We hope to see this March!

Cheers, 
The Government Programs Team

Opt-in for GP updates
GP Twitter